March 12, 2020
Takeda Pharmaceutical said on March 10 that its multiple myeloma treatment Ninlaro (ixazomib) failed to meet its primary endpoint of progression-free survival (PFS) in a multinational PIII clinical trial in patients with newly diagnosed multiple myeloma (MM) who are not...read more